Neurocrine Biosciences (NASDAQ: NBIX) shareholders should be pleased with the stock so far in 2019. The biotech's share price is up more than 30% year to date. And it reported solid revenue growth in its first-quarter results announced in April.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,